Transcutaneous immunization: An emerging route of immunization and potent immunostimulation strategy

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 5, 2001, Pages 503-525

  Hammond, S A ^a   Guebre Xabier, M ^a   Yu, J ^a   Glenn, G M ^a  

^a IOMAI Corporation   (United States)

Author keywords

Cholera toxin; CT; Heat labile enterotoxin of E. coli; Langerhans cells; LT; TCI; Transcutaneous immunization

Indexed keywords

2 PROPANOL; ALUMINUM POTASSIUM SULFATE; BACTERIAL DNA; BOVINE SERUM ALBUMIN; CHOLERA TOXIN; CYTOKINE; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; ESCHERICHIA COLI ENTEROTOXIN; EXOTOXIN; FREUND ADJUVANT; GELATIN; GLYCEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; POLYURETHAN; TETANUS TOXIN; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANTIGEN PRESENTATION; CELL ACTIVATION; DRUG FORMULATION; HUMAN; IMMUNIZATION; IMMUNOBIOLOGY; IMMUNOSTIMULATION; LANGERHANS CELL; MUCOSA; NONHUMAN; REVIEW; SIDE EFFECT; SKIN PENETRATION; VACCINATION;

EID: 0035206422     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i5.30     Document Type: Review

References (98)

1. A shot-gun optical map of the entire Plasmodium falciparum genome
2. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis
3. Vaccines and infectious disease
4. Vaccine developments
5. Water the most natural penetration enhancer
6. Epidermal Langerhans cells: From neurons to nature's adjuvants
7. Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy
8. Dermatologic formulations
9. Transdermal immunization with large proteins by means of ultradeformable drug carriers
10. Skin immunization made possible by cholera toxin
11. Phenotypic transformation of macrophages to Langerhans cells in the skin
12. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus
13. Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization
14. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate: Functional and morphological studies
15. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice
16. Vaccine adjuvants
17. Sur l'aumentation anormale de l'antitoxine chez les chevaux producteurs de serum antidipherique
18. Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system
19. Mutant heat-labile enterotoxins as adjuvants for CTL induction
20. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
21. Bacterial toxins as mucosal adjuvants
22. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
23. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins: Subunits and unrelated adjuvants
24. DNA-based non-invasive vaccination onto the skin
25. Adverse reactions to tetanus toxoid
26. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
27. Safety immunogenicity and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A cell wall skeleton of mycobacteria and squalane as adjuvant
28. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant
29. Effect of DETOX as an adjuvant for melanoma vaccine
30. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953
31. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
32. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines
33. Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines
34. Food allergy to gelatin in children with systemic immediate-type reactions including anaphylaxis to vaccines
35. IgE sensitization to gelatin: The probable role of gelatin-containing diphtheria-tetanus-acellular pertussis (DTaP) vaccines
36. Mechanisms of resistance to S. mansoni infection: The rat model
37. An overview of adjuvant use
38. Transcutaneous immunization: A human vaccine delivery strategy, using a patch
39. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
40. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
41. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: Implications for the augmentation of Th1 responses
42. Intradermal granulocyte-macrophage colony-stimulating factor alters cutaneous antigen-presenting cells and differentially affects local versus distant immunization in humans
43. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor
44. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
45. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
46. Activation of Langerhans cells following transcutaneous immunization
47. Phenotypic and functional characteristics of in vivo-activated Langerhans cells
48. Changes in epidermal Langerhans cells, gamma delta T cells, and CD4 T cells after intradermal infection with recombinant vaccinia virus-expressing cytokine genes
49. Langerhans cells at the sites of vaccinia virus inoculation
50. Maturation of epidermal Langerhans cells: Increased expression of beta- and gamma-actin isoforms as a basis of specialized cell functions
51. Activation pattern of Langerhans cells in the afferent and efferent phases of contact hypersensitivity
52. Heterogeneous reactivity of murine epidermal Langerhans cells after application of FITC: A histochemical evaluation
53. Transcutaneous immunization
54. Antigen-bearing Langerhans cells in skin dermal lymphatics and in lymph nodes
55. Immunization through dermal delivery of protein-encoding DNA: A role for migratory dendritic cells
56. DNA-based immunization by in vivo transfection of dendritic cells
57. Cadherins and Langerhans cell immunobiology
58. Phenotypic changes in Langerhans cells after infection with arboviruses: A role in the immune response to epidermally acquired viral infection
59. Transcutaneous immunization
60. Penetration enhancement by skin hydration
61. Advances in vaccine delivery: Transcutaneous immunisation
62. Cutaneous vaccination: The skin as an immunologically active tissue and the challenge of antigen delivery
63. Effect on systemic antibody concentrations of topical application of choleratoxin to skin of sheep
64. Transcutaneous immunization of domestic animals: Opportunities and challenges
65. Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract
66. Immunization via hair follicles by topical application of naked DNA to normal skin
67. The mechanism of cholera toxin adjuvanticity
68. Advances in vaccine adjuvants
69. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
70. Mucosal adjuvanticity and immunogenicity of LTR72 a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
71. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
72. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
73. Principles of transcutaneous immunization using cholera toxin as an adjuvant
74. Transcutaneous immunization: T-cell responses and boosting of existing immunity
75. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
76. Antitoxic immunity in experimental cholera: A comparison of immunity induced perorally and parenterally in mice
77. Antitoxic immunity in experimental cholera: Protection and serum and local antibody responses in rabbits after enteral and parenteral immunization
78. Antitoxic immunity to cholera in dogs immunized orally with cholera toxin
79. Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization
80. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli
81. Characterization of enterotoxigenic Escherichia coli isolated from U.S. troops deployed to the Middle East
82. Mucosal immunity to influenza without IgA: An IgA knockout mouse model
83. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone
84. Transcutaneous immunization
85. Diversity of antibody-mediated immunity at the mucosal barrier
86. Identification of secretory immunoglobulin A in human sweat and sweat glands
87. IgA in human skin appendages
88. Electron microscopic examination of Corynebacterium ovis
89. Immunoglobulins coat microorganisms of skin surface: A comparative immunohistochemical and ultrastructural study of cutaneous and oral microbial symbionts
90. Prospects for human mucosal vaccines
91. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit
92. Microanatomical distribution of dendritic cells in normal tonsils
93. Effects of IL-12 on immune responses induced by transcutaneous immunization with antigens formulated in a novel lipid-based biphasic delivery system
94. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process